Amaria, R. ., Prieto, P. ., Tetzlaff, M. ., Reuben, A. ., Andrews, M. ., Ross, M. ., … Wargo, J. . (2018). Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 19(2), 181-193. https://doi.org/10.1016/S1470-2045(18)30015-9

, Spencer, C. ., Nezi, L. ., Reuben, A. ., Andrews, M. ., Karpinets, T. ., … Wargo, J. . (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.), 359(6371), 97-103. https://doi.org/10.1126/science.aan4236 (Original work published 2018)

Wei, S. ., Levine, J. ., Cogdill, A. ., Zhao, Y. ., Anang, N. ., Andrews, M. ., … Allison, J. . (2017). Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 170(6), 1120-1133.e17. https://doi.org/10.1016/j.cell.2017.07.024 (Original work published 2017)